Zubero Z, Arrizabalaga J, Iribarren JA, Garde C, Santamaria JM, Munoz J; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 393 (abstract no. 2157).
Hospital Civil de Basurto. Bilbao. Spain
OBJECTIVE: Assessing the efficiency of Fansidar in preventing PCP relapses. METHODS: During the period comprised between January 1988 and August 1989, 42 patients presenting PCP started a secondary prophylaxis with Fansidar, one tablet a week, independent from the drugs used to treat the acute episode. In January 1990, the efectiveness of such medicament in preventing PCP relapses, as well as its toxicity, are evaluated. The effectiveness of the medicament as a primary prophylaxis in patients presenting a positive toxoplasma serology (PTS) is assessed as well, taking into account that 33% of AIDS cases within our field, with a PTS have presented toxoplasmic encephalitis. RESULTS: 2 PCP relapses (4.75%) have been recorded. The prophylaxis period has ranged between 2-23 months (x=10.8). The prophylaxis had to be stopped in 4 patients (9.5%) due to toxicity (3 of them about secondary granulopenia, 1 about dermic rash). 2 of 13 patients (15.3%) with a positive toxoplasma serology developed toxoplasmic encephalitis. CONCLUSION: Fansidar has proved efficient in preventing PCP relapses, offering low toxicity and easy dosification. The presence of toxoplasmic encephalitis has diminished more than 50% in patients taking Fansidar with a PTS.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antiretroviral Therapy, Highly Active
- Drug Combinations
- Drug Therapy, Combination
- Encephalitis
- Humans
- Pneumonia, Pneumocystis
- Pyrimethamine
- Sulfadoxine
- drug therapy
- methods
- sulfadoxine-pyrimethamine
- therapy
Other ID:
UI: 102197162
From Meeting Abstracts